Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation

Emmanuel Katsanis, Peter M. Anderson, Alexandra H. Filipovich, Diane E. Hasz, Mary L. Rich, Cynthia M. Loeffler, Augusto C. Ochoa, Daniel J. Weisdorf

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We evaluated the proliferation, cytolytic function, and phenotypic characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral blood mononuclear cells (PBMCs) from 44 patients with leukemia or non-Hodgkin's lymphoma (NHL) treated with multiagent chemotherapy or following bone marrow transplantation (BMT). BMT patients had decreased cell growth with only a 1.35 ± 0.25 (autologous BMT for acute lymphoblastic leukemia [ALL]), 1.24 ± 0.25 (autologous BMT for NHL), and 0.8 ± 0.1 (allogeneic BMT for leukemia) mean fold increase by day 5 of culture compared with controls (4.0 ± 0.4), P < .001. Anti-CD3 + IL-2 activated cells from patients with ALL and NHL who had received autologous BMT and cells from patients with leukemia who underwent allogeneic BMT were more effective in lysing the natural killer (NK) sensitive target, K562, and the NK-resistant target, Daudi, compared with controls. In contrast, cytolysis of K562 and Daudi by cultured PBMCs from patients with ALL and NHL receiving multi-agent chemotherapy was similar to that of controls. Cultures from BMT recipients had a significant increase in CD16+ (autologous ALL 5.7 ± 1.5%, P < .01; autologous NHL 12.4 ± 3.5%, P < .001; allogeneic 14.3 ± 2.9%, P < .001) and CD56+ cells (autologous ALL 27.6 ± 12.0%, P < .01; autologous NHL 39.3 ± 9.5%, P < .001; allogeneic 42.7 ± 7.4%, P < .001) compared with controls (CD16+ 2.5 ± 0.4%; CD56+ 6.9 ± 0.9%). Stimulation of PBMCs with anti-CD3 + IL-2 is effective in generating cells with high cytolytic function post-BMT.

Original languageEnglish (US)
Pages (from-to)1286-1291
Number of pages6
JournalBlood
Volume78
Issue number5
StatePublished - Sep 1 1991
Externally publishedYes

Fingerprint

Bone Marrow Transplantation
Interleukin-2
Blood Cells
Bone
Blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma
Autologous Transplantation
Leukemia
Chemotherapy
Homologous Transplantation
Drug Therapy
Cell growth
Bone Marrow Cells
Growth

ASJC Scopus subject areas

  • Hematology

Cite this

Katsanis, E., Anderson, P. M., Filipovich, A. H., Hasz, D. E., Rich, M. L., Loeffler, C. M., ... Weisdorf, D. J. (1991). Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Blood, 78(5), 1286-1291.

Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. / Katsanis, Emmanuel; Anderson, Peter M.; Filipovich, Alexandra H.; Hasz, Diane E.; Rich, Mary L.; Loeffler, Cynthia M.; Ochoa, Augusto C.; Weisdorf, Daniel J.

In: Blood, Vol. 78, No. 5, 01.09.1991, p. 1286-1291.

Research output: Contribution to journalArticle

Katsanis, E, Anderson, PM, Filipovich, AH, Hasz, DE, Rich, ML, Loeffler, CM, Ochoa, AC & Weisdorf, DJ 1991, 'Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation', Blood, vol. 78, no. 5, pp. 1286-1291.
Katsanis, Emmanuel ; Anderson, Peter M. ; Filipovich, Alexandra H. ; Hasz, Diane E. ; Rich, Mary L. ; Loeffler, Cynthia M. ; Ochoa, Augusto C. ; Weisdorf, Daniel J. / Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. In: Blood. 1991 ; Vol. 78, No. 5. pp. 1286-1291.
@article{27b48aa486034c9aa68b54d081a6bae9,
title = "Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation",
abstract = "We evaluated the proliferation, cytolytic function, and phenotypic characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral blood mononuclear cells (PBMCs) from 44 patients with leukemia or non-Hodgkin's lymphoma (NHL) treated with multiagent chemotherapy or following bone marrow transplantation (BMT). BMT patients had decreased cell growth with only a 1.35 ± 0.25 (autologous BMT for acute lymphoblastic leukemia [ALL]), 1.24 ± 0.25 (autologous BMT for NHL), and 0.8 ± 0.1 (allogeneic BMT for leukemia) mean fold increase by day 5 of culture compared with controls (4.0 ± 0.4), P < .001. Anti-CD3 + IL-2 activated cells from patients with ALL and NHL who had received autologous BMT and cells from patients with leukemia who underwent allogeneic BMT were more effective in lysing the natural killer (NK) sensitive target, K562, and the NK-resistant target, Daudi, compared with controls. In contrast, cytolysis of K562 and Daudi by cultured PBMCs from patients with ALL and NHL receiving multi-agent chemotherapy was similar to that of controls. Cultures from BMT recipients had a significant increase in CD16+ (autologous ALL 5.7 ± 1.5{\%}, P < .01; autologous NHL 12.4 ± 3.5{\%}, P < .001; allogeneic 14.3 ± 2.9{\%}, P < .001) and CD56+ cells (autologous ALL 27.6 ± 12.0{\%}, P < .01; autologous NHL 39.3 ± 9.5{\%}, P < .001; allogeneic 42.7 ± 7.4{\%}, P < .001) compared with controls (CD16+ 2.5 ± 0.4{\%}; CD56+ 6.9 ± 0.9{\%}). Stimulation of PBMCs with anti-CD3 + IL-2 is effective in generating cells with high cytolytic function post-BMT.",
author = "Emmanuel Katsanis and Anderson, {Peter M.} and Filipovich, {Alexandra H.} and Hasz, {Diane E.} and Rich, {Mary L.} and Loeffler, {Cynthia M.} and Ochoa, {Augusto C.} and Weisdorf, {Daniel J.}",
year = "1991",
month = "9",
day = "1",
language = "English (US)",
volume = "78",
pages = "1286--1291",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation

AU - Katsanis, Emmanuel

AU - Anderson, Peter M.

AU - Filipovich, Alexandra H.

AU - Hasz, Diane E.

AU - Rich, Mary L.

AU - Loeffler, Cynthia M.

AU - Ochoa, Augusto C.

AU - Weisdorf, Daniel J.

PY - 1991/9/1

Y1 - 1991/9/1

N2 - We evaluated the proliferation, cytolytic function, and phenotypic characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral blood mononuclear cells (PBMCs) from 44 patients with leukemia or non-Hodgkin's lymphoma (NHL) treated with multiagent chemotherapy or following bone marrow transplantation (BMT). BMT patients had decreased cell growth with only a 1.35 ± 0.25 (autologous BMT for acute lymphoblastic leukemia [ALL]), 1.24 ± 0.25 (autologous BMT for NHL), and 0.8 ± 0.1 (allogeneic BMT for leukemia) mean fold increase by day 5 of culture compared with controls (4.0 ± 0.4), P < .001. Anti-CD3 + IL-2 activated cells from patients with ALL and NHL who had received autologous BMT and cells from patients with leukemia who underwent allogeneic BMT were more effective in lysing the natural killer (NK) sensitive target, K562, and the NK-resistant target, Daudi, compared with controls. In contrast, cytolysis of K562 and Daudi by cultured PBMCs from patients with ALL and NHL receiving multi-agent chemotherapy was similar to that of controls. Cultures from BMT recipients had a significant increase in CD16+ (autologous ALL 5.7 ± 1.5%, P < .01; autologous NHL 12.4 ± 3.5%, P < .001; allogeneic 14.3 ± 2.9%, P < .001) and CD56+ cells (autologous ALL 27.6 ± 12.0%, P < .01; autologous NHL 39.3 ± 9.5%, P < .001; allogeneic 42.7 ± 7.4%, P < .001) compared with controls (CD16+ 2.5 ± 0.4%; CD56+ 6.9 ± 0.9%). Stimulation of PBMCs with anti-CD3 + IL-2 is effective in generating cells with high cytolytic function post-BMT.

AB - We evaluated the proliferation, cytolytic function, and phenotypic characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral blood mononuclear cells (PBMCs) from 44 patients with leukemia or non-Hodgkin's lymphoma (NHL) treated with multiagent chemotherapy or following bone marrow transplantation (BMT). BMT patients had decreased cell growth with only a 1.35 ± 0.25 (autologous BMT for acute lymphoblastic leukemia [ALL]), 1.24 ± 0.25 (autologous BMT for NHL), and 0.8 ± 0.1 (allogeneic BMT for leukemia) mean fold increase by day 5 of culture compared with controls (4.0 ± 0.4), P < .001. Anti-CD3 + IL-2 activated cells from patients with ALL and NHL who had received autologous BMT and cells from patients with leukemia who underwent allogeneic BMT were more effective in lysing the natural killer (NK) sensitive target, K562, and the NK-resistant target, Daudi, compared with controls. In contrast, cytolysis of K562 and Daudi by cultured PBMCs from patients with ALL and NHL receiving multi-agent chemotherapy was similar to that of controls. Cultures from BMT recipients had a significant increase in CD16+ (autologous ALL 5.7 ± 1.5%, P < .01; autologous NHL 12.4 ± 3.5%, P < .001; allogeneic 14.3 ± 2.9%, P < .001) and CD56+ cells (autologous ALL 27.6 ± 12.0%, P < .01; autologous NHL 39.3 ± 9.5%, P < .001; allogeneic 42.7 ± 7.4%, P < .001) compared with controls (CD16+ 2.5 ± 0.4%; CD56+ 6.9 ± 0.9%). Stimulation of PBMCs with anti-CD3 + IL-2 is effective in generating cells with high cytolytic function post-BMT.

UR - http://www.scopus.com/inward/record.url?scp=0026001155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026001155&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 1286

EP - 1291

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -